Nutrition Notes, Feb, 2017 from Roc Nutrition Investigator
Maret Traber, a professor in the Oregon State University College of Public Health and Human Sciences, and Ava Helen Pauling, Professor in the Linus Pauling Institute, said “the research showed that people with metabolic syndrome need about 30-50 per cent more vitamin E
Science 3 Feb pg 457 – Sleep is a universal phenomenon in the animal kingdom, and lack of sleep leads to severe cognitive disruption. There are two main schools of thought why sleep is necessary. One is maintenance, repairing wear and tear, replenishing energy and clearing waste. The other is “information processing”, such as memory consolidation. It has just been discovered that contacts across synapses decrease during sleep, though why is unclear.
Science 17 Feb pg 688 – Vitamin B3 protects eye degeneration in glaucoma and restored some sight in mice. Thus B3 supplements may be useful to preserve vision if you have glaucoma. Also, NAD+ (niacin, vitamin B3-related compound) decreases with age, and supplements can prolong both health span and life span, esp. neurodegenerative disease. Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in all living cells. Here we review factors that regulate NAD+ and discuss how supplementation with NAD+ precursors may represent a new therapeutic opportunity for aging and its associated disorders, particularly neurodegenerative diseases.
Science 20 Jan pg 230 – GRE scores and undergraduate GPA don’t predict graduate school productivity-but reference letters do.
Science 20 Jan pg 228 – National Academy of Sciences report states that using marijuana does help chronic pain! Also, NPR reports a study stating for back pain, using pain killers to mask the pain causes more damage. Doing yoga is the best thing to relieve and prevent back pain.
Too much calcium (as in most calcium supplements) is hazardous to your heart. High coronary calcium score and post procedural CK MB are noninvasive predictors of coronary stent restenosis https://www.dovepress.com/article_31382.t65941372
Person-centered care interventions were shown to reduce agitation, neuropsychiatric symptoms, and depression and to improve the quality of life. Person-centered care interventions can effectively reduce agitation for a short term using intensive and activity-based intervention. However, an educational strategy that promotes learning and skill development of internal care staff is needed to enhance patient’s quality of life and to ensure the sustainability of the effects of behavioral problems.
https://www.dovepress.com/article_31398.t65941372
“The days of the God-doctor are over. Between the role of genomics, a better understanding of the human animal, and emergence of Internet technologies, we are moving toward a future where 99% of our medical care will be a matter of self-management and self-responsibility.” Juhan Sonin, Determinants of Health model which maps 29 macro-determinants and 66 micro-determinants that influence the health of an individual.
The factors that significantly predicted poorer benefits from exercise training outcomes in older adults in nursing homes were having a neurological disease other than stroke, having dizziness/balance problems as the major health condition and having pain/discomfort. In addition, having anxiety/depression was a predictor of poorer COPM-P outcomes.
READERS QUESTION: Coffee is the new “health drink”! Do you have access to any studies showing correlation between coffee intake and breast cancer? Women who drink more than five cups of coffee a day may be reducing their risk of one type of breast cancer, new research suggests.
READERS COMMENT: Look at low-dose naltrexone for cancer!
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn’s disease, multiple sclerosis, and complex regional pain syndrome. LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone’s better-known activity on opioid receptors. As a daily oral therapy, LDN is inexpensive and well-tolerated. Despite initial promise of efficacy, the use of LDN for chronic disorders is still highly experimental. Published trials have low sample sizes, and few replications have been performed. We cover the typical usage of LDN in clinical trials, caveats to using the medication, and recommendations for future research and clinical work. LDN may represent one of the first glial cell modulators to be used for the management of chronic pain disorders.
– Roc, Nutrition Investigator
*To be added or removed from the nutrition research Email List . *To review the disclaimer*To ask Roc a question. https://nutritioninvestigator.org/Ordman/
“Nothing is so firmly believed as that which a man knoweth least.” Montaigne
